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Background
An increased risk of RA has been described in smokers,
but only in ACPA-positive RA patients. The frequency
of ACPA in serum of heavy smokers is not known.
Objectives
Analyze the serum frequency and levels of ACPA on heavy
smoker subjects, with and without chronic obstructive
pulmonary disease (COPD), and compare them with a
healthy control group.
Methods
Serum samples of 110 heavy smokers (39% women,
56.9±10 years) were obtained.
Subjects were selected from a Pneumology Service
database and from hospital workers. They were com-
pared with 209 healthy controls who had never smoked
(51% women, 41.8±12 years). Both groups were tested
for two different antibodies against citrullinated pro-
teins, a commercial anti-CCP2 test and a home-made
chimeric fibrin/filaggrin citrullinated synthetic peptide
(anti-CFFCP).
Their frequency and levels were compared between
groups.
Results
Of the 110 heavy smokers, 54 had COPD and 56 were
healthy smokers. None had RA. Mean packs-year were
44.3±36 (53±28 in COPD disease and 36±16 in healthy
smokers, p<0.01).
Percentage of positive results and mean serum levels
of ACPA in all the study groups are shown in Table 1.
The prevalence of positive anti-CFFCP was higher in
the heavy smoker group than in non-smokers,
although the difference was not significant. The high-
est prevalence of positive anti-CFFCP was seen in
patients with COPD (7.4%); the difference was at the
limit of statistical significance compared with the con-
trol group (2.4%) (OR:3.26 95% CI:0.85-12.6 p=0.07).
Heavy smokers with COPD had significantly higher
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Table 1 Frequency of positive autoantibodies and mean serum levels of antibodies in the study groups
HEAVY SMOKERS NON SMOKERS
A TOTAL n=110 B COPD n=54 C NON COPD n=56 D n=209
CFFCP+ (%) 5 (4.5%) 4 (7.4%)* 1 (1.7%) 5 (2.4%)*
CFFCP mean±SD 0.12±0.06 0.15±0.7† ¶ 0.09±0.5† 0.10±0.12¶
CCP2+ (%) 2 (1.8%) 2 (3.7%) 0 (0%) 4 (1.9%)
CCP2 mean ±SD 15.62±4.25 16.2±5.97‡ 15.05±0.9‡ 16.9±2.78
*B vs D p=0.07, †B vs C p<0.001, ¶B vs D p=0.02, ‡B vs C p=0.17.
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levels of both autoantibodies than non-smokers and
smokers without COPD.
Conclusion
The prevalence of ACPA in heavy smokers without RA
is low, but seems to be higher in heavy smokers with
COPD. Larger studies are necessary to confirm these
findings and determine the relationship between ACPA
and lung disease.
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